Literature DB >> 20584722

The impact of HLA-DRB alleles on the subclass titres of antibodies against citrullinated peptides.

Robby Engelmann1, Martin Eggert, Gunther Neeck, Brigitte Mueller-Hilke.   

Abstract

OBJECTIVES: The association between HLA-DR haplotypes and RA have been well established. However, the molecular mechanisms of how HLA mediates susceptibility and/or progression of the disease remain elusive. We therefore turned to the RA-specific antibodies directed against citrullinated peptide antigens (ACPAs) and investigated the association between HLA-DRB1 shared epitope (SE) alleles and the IgG subclass titres of cyclic citrullinated peptide (CCP)- and mutated citrullinated vimentin (MCV)-specific antibodies.
METHODS: One hundred and twenty-seven RA patients were typed for their HLA-DRB1 haplotypes applying low resolution and alleles potentially carrying the SE were sequenced. All patients' sera were analysed by ELISA for the presence of ACPA and 77 patients positive for CCP-specific antibodies were further analysed for the respective IgG subclasses. Subclass titres were then correlated to the presence of a SE. Finally, all patients were screened for the HLA-DRB4-associated splice variant.
RESULTS: We found a gene dosage effect of the HLA-DRB1*04-associated SE on both the MCV- and CCP-specific IgG3 levels. The HLA-DRB4-associated splice variant accumulates in ACPA-negative RA patients.
CONCLUSIONS: Both the dose-dependent increase in IgG3 among ACPA and the accumulation of the splice variant in ACPA-negative patients imply differential expression of the HLA alleles as the mechanism contributing to the susceptibility and/or disease progression of RA. The preponderance of IgG3 hints at a skewing towards a Th1 response and is reminiscent of increased signal strengths at the immunological synapse. Likewise, the abrogation of HLA-DRB4 expression due to the splice variant reduces the signal strength and seems to protect from ACPA development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584722     DOI: 10.1093/rheumatology/keq179

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

2.  Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis.

Authors:  Johannes R Hov; Vasilis Kosmoliaptsis; James A Traherne; Marita Olsson; Kirsten M Boberg; Annika Bergquist; Erik Schrumpf; J Andrew Bradley; Craig J Taylor; Benedicte A Lie; John Trowsdale; Tom H Karlsen
Journal:  Hepatology       Date:  2011-05-13       Impact factor: 17.425

3.  Genetic polymorphism of rs9277535 in HLA-DP associated with rheumatoid arthritis and anti-CCP production in a Chinese population.

Authors:  Zhuochun Huang; Qian Niu; Bin Yang; Junlong Zhang; Min Yang; Huan Xu; Bei Cai; Jing Hu; Yongkang Wu; Lanlan Wang
Journal:  Clin Rheumatol       Date:  2018-02-23       Impact factor: 2.980

Review 4.  The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.

Authors:  Katleen Van Steendam; Kelly Tilleman; Dieter Deforce
Journal:  Rheumatology (Oxford)       Date:  2011-01-27       Impact factor: 7.580

5.  HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients.

Authors:  Pieter W A Meyer; Bridget Hodkinson; Mahmood Ally; Eustasius Musenge; Ahmed A Wadee; Heidi Fickl; Mohammed Tikly; Ronald Anderson
Journal:  Arthritis Res Ther       Date:  2011-10-06       Impact factor: 5.156

6.  Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease.

Authors:  Kazuhiro Kiyama; Hajime Yoshifuji; Tsugumitsu Kandou; Yuji Hosono; Koji Kitagori; Ran Nakashima; Yoshitaka Imura; Naoichiro Yukawa; Koichiro Ohmura; Takao Fujii; Daisuke Kawabata; Tsuneyo Mimori
Journal:  BMC Musculoskelet Disord       Date:  2015-05-28       Impact factor: 2.362

7.  Anti-citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se.

Authors:  Dan Murphy; Derek Mattey; David Hutchinson
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.